Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#3581 Pancreatic neuroendocrine tumors (PanNETs) vascularization: From “micro” to “macro”

Introduction: Density of microvessels in pancreatic neuroendocrine tumors (PanNETs) changes according to their biological behaviour. Differently from other non-neuroendocrine cancers, a low microvessel density (L-MVD) is associated with higher disease aggressiveness and poorer prognosis.

Conference:

Presenting Author:

Authors: Battistella A, Andreasi V, Palumbo D, Tacelli M, de Cobelli F,

Keywords: pancreatic neuroendocrine tumor, microvessel density, imaging, computed tomography, endoscopic ultrasound, vascularization, enhancement, washout,

#1714 CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)

Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Meyer T

Authors: Meyer T, Higgs K, Hickling M, Houchard A,

Keywords: midgut neuroendocrine tumor, CTC, lanreotide,

#76 Role of contrast-enhanced ultrasonography in the differential diagnosis of the pancreatic and hepatic lesions

Introduction: Contrast-enhanced ultrasonography (CEUS) is a new promising tool for the characterization of pancreatic lesions. This technique allows for highlighting the micro-vascularization of a lesion, especially with the use of second generation contrast media, characterized by harmonic responses at low acoustic pressures. Pancreatic endocrine tumors (PET)s were reported to have a peculiar behavior at CEUS, consisting of a higher enhancement compared to normal pancreas in the arterial phase and a rapid washout.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Milone F

Authors: Milone F, Di Sarno A, Faggiano A, Farella N, Ramundo V,

Keywords: pancreatic neuroendocrine tumors, differential diagnosis, contrast-enhanced ultrasonography,